查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918110

骨科生物製剂市场－2026-2031年预测

Orthobiologics Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 152 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

骨科生物製剂市场预计将从 2025 年的 68.16 亿美元成长到 2031 年的 88.77 亿美元，复合年增长率为 4.5%。

骨科生物製剂市场正经历显着成长，这主要得益于临床需求、人口趋势和技术创新三者的共同推动。这些产品由生物来源材料製成，用于治疗肌肉骨骼疾病，在治疗急性和慢性骨骼、关节和软组织疾病方面变得日益重要。全球肌肉骨骼疾病的增加、创伤性损伤的增加以及对先进生物治疗方法的关注，都进一步促进了市场扩张。

骨骼疾病和肌肉骨骼疾病在全球日益普遍，是推动市场发展的关键因素。骨关节炎、骨质疏鬆症和慢性关节疼痛等疾病是全球范围内导致残疾的重要且不断增长的原因。如此高的发病率造就了庞大且持续的患者群体，他们需要有效的整形外科干预措施，从而产生了对能够促进癒合和缓解疼痛的骨科生物製剂的潜在需求。

同时，运动相关伤害和道路交通事故发生率的上升也是市场成长的主要驱动力。这些损伤通常会导致骨骼、关节和软组织严重受损，需要先进的修復和再生治疗。全球范围内全年此类损伤的大量发生，确保了对用于外科手术和治疗的骨科生物製剂产品持续且显着的需求，这些产品旨在恢復功能并加速康復。

人口结构变化也对市场产生了显着影响。全球人口老化是主要因素之一，老年人尤其容易罹患骨关节炎和骨质疏鬆症。这一人口趋势与需要整形外科治疗的疾病发生率的增加直接相关，从长远来看，这将扩大骨科生物製剂的目标患者群体。此外，可支配收入的增加和生活水准的提高，尤其是在开发中国家，正在扩大人们获得先进医疗服务的机会。随着患者寻求更有效、更舒适的治疗方案，对先进骨科生物製剂的需求也预计将随之成长。

在企业研发和政府主导的各项措施的支持下，技术进步是推动市场发展的关键因素。大量的公共和私人投资正涌入下一代再生医学技术的研究领域，包括用于骨骼和软骨再生的注射解决方案。这种对创新的执着追求不断拓展骨科生物製剂的治疗能力和临床应用，从而催生出充满活力的新产品和治疗方法。

北美作为关键市场，其特点是肌肉骨骼疾病（尤其是关节炎）高发生率、监管和临床基础设施完善，以及许多大型医疗设备公司的存在。该地区对技术应用的高度重视和成熟的医疗保健生态系统巩固了其主导地位。

亚太地区已成为成长最快的市场之一。这一增长主要得益于高发生率的道路交通事故、不断增长的医疗费用支出以及政府投资推动的持续技术进步。该地区庞大的人口基数和快速发展的医疗基础设施为市场扩张提供了巨大的机会。

竞争格局包括Alphatec Spine、Earthtrex和Bioventus等专业公司，它们专注于开发脊椎手术、关节修復和疼痛管理的综合解决方案，并透过持续的产品创新来维持市场地位。该行业每年推出的新产品数量众多，反映出竞争激烈且创新主导的环境，旨在改善手术效果并满足肌肉骨骼疾病患者的复杂需求。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

5. 全球骨科生物製剂市场（依产品划分）

  • 介绍
  • 干细胞疗法
  • PRP
  • 关节内粘稠补充疗法
  • 骨髓抽吸浓缩液（BMCA）
  • 其他的

6. 全球骨科生物製剂市场（依应用划分）

  • 介绍
  • 韧带和肌腱损伤
  • 骨关节炎和退化性关节炎
  • 脊椎融合手术
  • 其他的

7. 全球骨科生物製剂市场（依最终用户划分）

  • 介绍
  • 医院
  • 整形外科诊所
  • 其他的

8. 全球骨科生物製剂市场（按地区划分）

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章：竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • Alphatec Spine, Inc.
  • Arthrex Inc.
  • Bioventus LLC
  • Exactech, Inc.
  • Integra Lifesciences
  • Medtronic Plc
  • MTF Biologics
  • Zimmer Biomet
  • Stryker Corporation
  • Johnson & Johnson
  • NuVasive

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615581

The orthobiologics market is projected to expand at a 4.5% CAGR, attaining USD 8.877 billion in 2031 from USD 6.816 billion in 2025.

The orthobiologics market is experiencing significant growth, driven by the convergence of clinical demand, demographic trends, and technological innovation. These products, which are derived from biological substances and used to treat musculoskeletal conditions, are becoming integral to the management of acute and chronic bone, joint, and soft tissue disorders. The market's expansion is underpinned by a rising global burden of musculoskeletal disease, an increasing volume of traumatic injuries, and a shift towards advanced, biologically-driven treatment modalities.

A primary market driver is the escalating global prevalence of bone diseases and musculoskeletal defects. Conditions such as osteoarthritis, osteoporosis, and chronic joint pain represent a substantial and growing source of disability worldwide. This high prevalence establishes a large and sustained patient population in need of effective orthopedic interventions, creating a foundational demand for orthobiologic solutions that can enhance healing and alleviate pain.

Concurrently, the rising incidence of sports-related and road traffic injuries is a major contributor to market growth. These traumatic events frequently result in significant damage to bones, joints, and soft tissues, necessitating advanced reparative and regenerative treatments. The high annual global volume of such injuries ensures a consistent and significant demand for orthobiologic products used in surgical and therapeutic applications to restore function and accelerate recovery.

Demographic shifts are also profoundly influencing the market. The global aging population is a key factor, as older adults are disproportionately affected by degenerative joint diseases and osteoporosis. This demographic trend directly correlates with an increased incidence of conditions requiring orthopedic care, thereby expanding the addressable patient base for orthobiologic therapies over the long term. Furthermore, rising disposable incomes and improving living standards, particularly in developing economies, are enabling greater access to advanced medical treatments. As patients seek more effective and comfortable care, the demand for sophisticated orthobiologic solutions is expected to rise correspondingly.

Technological advancement, supported by both corporate R&D and governmental initiatives, is a critical force propelling the market forward. Significant public and private investments are being channeled into research focused on next-generation regenerative technologies, including injectable solutions for bone and cartilage regeneration. This commitment to innovation is continuously expanding the therapeutic capabilities and clinical applications of orthobiologics, fostering a dynamic pipeline of new products and treatment approaches.

Geographically, North America is a dominant market, characterized by a high prevalence of arthritis and other musculoskeletal conditions, a robust regulatory and clinical infrastructure, and the presence of leading medical device companies. The region's strong focus on technological adoption and its mature healthcare ecosystem consolidate its leadership position.

The Asia-Pacific region is emerging as one of the fastest-growing markets. This growth is fueled by a high incidence of road traffic accidents, increasing healthcare expenditure, and ongoing technological advancements supported by government investment. The region's large population and rapidly developing healthcare infrastructure present a substantial opportunity for market expansion.

The competitive landscape includes specialized players such as Alphatec Spine, Arthrex, and Bioventus. These companies maintain their market positions through continuous product innovation, with a focus on developing comprehensive solutions for spine surgery, joint restoration, and pain management. The industry's high rate of new product introductions each year reflects a intensely competitive and innovation-driven environment, aimed at improving surgical outcomes and addressing the complex needs of patients with musculoskeletal disorders.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Orthobiologics Market Segmentation:

  • By Product
  • Stem Cell Therapy
  • PRP
  • Viscosupplementation
  • Bone Marrow Aspirate Concentrate (BMAC)
  • Others
  • By Application
  • Ligament & Tendon Injury
  • Osteoarthritis & Degenerative Arthritis
  • Spinal Fusion
  • Others
  • By End-User
  • Hospitals
  • Orthopedic Clinics
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL ORTHOBIOLOGICS MARKET BY

  • 5.1. Introduction
  • 5.2. Stem Cell Therapy
  • 5.3. PRP
  • 5.4. Viscosupplementation
  • 5.5. Bone Marrow Aspirate Concentrate (BMCA)
  • 5.6. Others

6. GLOBAL ORTHOBIOLOGICS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Ligament & Tendon Injury
  • 6.3. Osteoarthritis & Degenrative Arthritis
  • 6.4. Spinal Fusion
  • 6.5. Others

7. GLOBAL ORTHOBIOLOGICS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Orthopedo Clinics
  • 7.4. Others

8. GLOBAL ORTHOBIOLOGICS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Italy
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Alphatec Spine, Inc.
  • 10.2. Arthrex Inc.
  • 10.3. Bioventus LLC
  • 10.4. Exactech, Inc.
  • 10.5. Integra Lifesciences
  • 10.6. Medtronic Plc
  • 10.7. MTF Biologics
  • 10.8. Zimmer Biomet
  • 10.9. Stryker Corporation
  • 10.10. Johnson & Johnson
  • 10.11. NuVasive

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations